SEC form
4
Accepted by SEC
18 Nov 2026, 16:36:03 UTC
Prior SEC filing
18 Mar 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Anni Lotte Kirstine Sonderbjerg Pedersen filed Form 4 for Ascendis Pharma A/S (ASND) on 18 Nov 2026.

Key facts

  • This page summarizes Anni Lotte Kirstine Sonderbjerg Pedersen's Form 4 filing for Ascendis Pharma A/S (ASND).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 18 Nov 2026, 16:36.

Change

  • Previous filing in this sequence was filed on 18 Mar 2026.
  • Current net transaction value: -$5,277,720.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001965755 Primary reporting owner

PEDERSEN ANNI LOTTE KIRSTINE SONDERBJERG

Relationship
EVP & Chief Admin Officer

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ASND transaction

Ordinary Shares

Options Exercise

Transaction value
Shares
+20,000
Change %
+103%
Price
$37.18*
Shares after
39,460
Date
17 Nov 2026
Ownership
Direct
ASND transaction

Ordinary Shares

Sale

Transaction value
-$5,277,720
Shares
-20,000
Change %
-51%
Price
$263.89
Shares after
19,460
Date
17 Nov 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ASND transaction Derivative

Warrants

Options Exercise

Transaction value
Shares
-20,000
Change %
-100%
Price
$0.000000*
Shares after
0
Date
17 Nov 2026
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
20,000
Exercise price
$37.18
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The warrants are fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .